Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-08-03
2010-12-14
Vivlemore, Tracy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C514S04400A
Reexamination Certificate
active
07851615
ABSTRACT:
The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.
REFERENCES:
patent: 4572912 (1986-02-01), Yoshioka et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5646126 (1997-07-01), Cheng et al.
patent: 6147204 (2000-11-01), Gold et al.
patent: 6239107 (2001-05-01), Gozes et al.
patent: 6509323 (2003-01-01), Davis et al.
patent: 2002/0016285 (2002-02-01), Bhatt et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2003/0008818 (2003-01-01), Pun et al.
patent: 2003/0170891 (2003-09-01), McSwiggen
patent: 2005/0107325 (2005-05-01), Manoharan et al.
patent: 2005/0119214 (2005-06-01), Manoharan et al.
patent: 2005/0164235 (2005-07-01), Manoharan et al.
patent: 2006/0058266 (2006-03-01), Manoharan et al.
patent: 0023725 (1981-02-01), None
patent: WO 9203464 (1992-03-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 00/44914 (2000-08-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 01/98273 (2001-12-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 03/051839 (2003-06-01), None
patent: WO 2004/065601 (2004-08-01), None
patent: WO 2005/061499 (2005-07-01), None
Levin et al. “Rapid, One-Pot Conversion of Aryl Fluorides into Phenols with 2-Butyn-1-Ol and Potassium t-Butoxide in Dmso”. Synthetic Communications 32(9):1401-1406, 2002.
Rogers et al. “Mild conversion of electron deficient aryl fluorides to phenols using 2-(methylsulfonyl)ethanol”. Tetrahedron Letters 43:3585-3587, 2002.
Wirz et al. “Facile chemoenzymatic preparation of enantiomerically pure 2-methylglycerol derivatives as versatile trifunctional C4-synthons”. J. Org. Chem. 58:3980-3984, 1993.
Sajiki et al. “Highly chemoselective drdrogenation with retention of the epoxide function using a heterogeneous Pd/C—Ethylenediamine catalyst and THF”. Chem. Eur. J. 6(12):2200-2204, 2000.
Amosova el al., “Effect of the 1-(2′-deoxy-beta-D-ribofuranosyl)-3-nitropyrrole residue on the stability of DNA duplexes and triplexes”Nucleic Acids Res.25:1930-1934—(1997.
An et al., “Synthesis of Novel 3 ′-C-Methylene Thymidinc and 5-Methyluridine/Cytidine H-Phosphonates and Phosphonamidites for New Backbone Modification of Oligonucleotides”J. Org. Chem.66:2789-2801 (2001).
Ausin et al., “Synthesis of Amino- and Guanidino-G-Clamp PNA Monomers”Organic Letters4:4073-4075 (2002).
Aoki et al., “Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD MOTIF”Cancer Gene Therpy8:783-787 (2001).
Basbaum et al, “Focalized proteolysis: spatial and temporal regulation of extra cellular matrix degradation at the cell surface”Curr. Opin. Cell Biol.8:731-738 (1996).
Benezra et al., “The Id proteins and angiogenesis”Oncogene20(58):8334-41 (2001).
Berger et al., “Universal bases for hybridization, replication and chain termination”Nucleic Acids Res.28:2911-2914 (2000).
Bergstrom et al., “Synthesis, Structure, and Deoxyribonucleic Acid Sequencing with a Universal Nucleoside: 1-(2′-Deoxy-β-D-ribofuranosyl)-3-nitropyrrole”Am. Chem. Soc.117:1201-1209 (1995).
Bernstein et al., “Role for a bidentate ribonuclease in the initiation step of RNA interference”Nature409:363-366 (2001).
Birkedal-Hansen et al., “Matrix Metalloproteinases: A Review”Crit. Rev. Oral Biol. Med.4:197-250 (1993).
Boyd, “Invasion and metastasis”Cancer Metastasis Rev.15(1):77-89 (1996).
Brinckerhoff et al., “Matrix metalloproteinases: a tail of a frog that became a prince”Nature Reviews3:207-214 (2002).
Brotschi et al., “A Stable DNA Duplex Containing a Non-Hydrogen-Bonding and Non-Shape-Complementary Base Couple: Interstrand Stacking as the Stability Determining Factor”Agnew Chem. Int. Ed.40:3012-3014 (2001).
Chaloin et al., “Design of Carrier Peptide-Oligonucleotide Conjugates with Rapid Membrane Translocation and Nuclear Localization Properties”Biochem. Biophys. Res. Commun.243:601 608 (1998).
Chao et al., “BCL-2 Family: Regulators of Cell Death”Annu. Rev. Immunol.16:395-419 (1998).
Chen et al., “Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo”Proc. Natl. Acad. Sci. USA91:3054-3057 (1994).
Childs et al., “The MDR Superfamily of Genes and Its Biological Implications”Imp. Adv. Oncol.21-36 (1994).
Chothia et al, “The Molecular Structure of Cell Adhesion Molecules”Annu. Rev. Biochem.66:823-862 (1997).
Colledge et al., “Disruption of c-mos causes parthenogenetic development of unfertilized mouse eggs”Nature370: 65-68 (1994.
Corey et al., “Protection of Hydroxyl Groups astert-Butyldimethylsilyl Derivatives”J. Am. Chem. Soc.94:6190-6191 (1972).
Cormier et al., “Synthesis of hexanucleotide analogues containing diisopropylsilyl internucleotide linkages”Nucleic Acids Res.16:4583-4594 (1988).
Cosstick et al, “Solid Phase Synthesis of Oligonucleotides Containing 3′-Thiothymidine”Tetrahedron Lett.30(35):4693-4039 (1989).
D'Ari, “Cycle-regulated genes and cell cycle regulation”Bioassays23(7):563-565 (2001).
De et al, “Structure-Activity Relationships for Antiplasmodial Activity among 7-Substituted 4-Aminoquinolines”J. Med. Chem.41:4198-4926 (1998).
Deller et al., “Cell surface receptors”Curr. Opin. Struct. Biol.10(2):213-219 (2000).
Derossi et al., “The Third Helix of the Antennapedia Homeodomain Translocates through Biological Membranes”J. Biol. Chem.269(14):10444-10450 (1994).
Eckstein, “Oligonucleotides and Analogues, A practical approach” Table of ContentsIRL Press(1991).
Edge, et al., “Synthetic Analogues of Polynucleotides. Part VIII. Analogues of Oligonucleotides containing Carboxymethylthymidine”J. Chem. Soc. Perkin Trans.1:1991-1996 (1972).
Elbashir et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs”Genes and Dev.15:188-200 (2001).
Elmquist et al., “VE-Cadherin-Derived Cell-Penetrating Peptide, pVEC, with Carrier Functions”Exp. Cell Res.269:237-244 (2001).
Fang et al., “Fluoride-cleavable biotinylation phosphoramidite for 5′-end-labeling and affinity purification of synthetic oligonucleotides”Nucleic Acids Res.31(2):708-715 (2003).
Fire et al., “Potent specific genetic interference by double-stranded RNA inCaenorhabditis elegans”Nature391:806-811 (1998).
Fischer et al., “Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation”Bioconjugate Chem.12:825-841 (2001).
Flanagan et al., “A cytosine analog that confers enhanced potency to antisense oligonucleotides”Proc. Natl. Acad. Sci. USA96:3513-3518 (1999).
Fotedar et al., “Apoptosis and the cell cycle”Prog. Cell Cycle Res.2:147-163 (1996).
Gante, “Azapeptides”Synthesis405-413 (1989).
Gould et al., “Angiogenesis: An Expanding Universe”Hum. Pathol.33(11):1061-1063 (2002).
Guckian et al., “Structure and Base Pairing Properties of a Replicable Nonpolar Isostere for Deoxyadenosine”J. Org. Chem.63:9652-9656 (1998).
Hammond, “Argonaute2, a link between genetic and biochemical analyses of RNAi”Science293:1146-1150 (2001).
Hashimoto et al., “Parthenog
Manoharan Muthiah
Rajeev Kallanthottahil G.
Alnylam Pharmaceuticals, Inc.
Nixon & Peabody LLP
Townes Jeffrey N.
Vivlemore Tracy
LandOfFree
Lipophilic conjugated iRNA agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipophilic conjugated iRNA agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipophilic conjugated iRNA agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4211604